NCT05261438已完成不适用
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2019年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
详细描述
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel
排除标准
- •Patients with contraindication of chemotherapy Pregnant or breast feeding women
结局指标
主要结局
OS
时间窗: September 2019- september 2021
overall survival
PFS
时间窗: September 2019- september 2021
progression-free survival
次要结局
未报告次要终点
研究者
Yongchang Zhang
HunanPTH
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerMetastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaStage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8Thyroid Gland Anaplastic CarcinomaUnresectable Thyroid Gland CarcinomaNCT03181100M.D. Anderson Cancer Center50
已完成
3 期
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerTriple Negative Breast NeoplasmsNCT03371017Hoffmann-La Roche595
终止
2 期
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaUrothelial CarcinomaNCT03737123Nabil Adra6
终止
2 期
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerUrothelial CarcinomaNCT03272217Arjun Balar, MD16
已完成
3 期
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaUrothelial CarcinomaNCT02807636Hoffmann-La Roche1,213